Dr. Margolin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
113 Hartwell St
Lexington, MA 02421
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1991 - 1994
Graduate HospitalInternship, Internal Medicine, 1990 - 1991
Perelman School of Medicine at the University of PennsylvaniaClass of 1990
Certifications & Licensure
MA State Medical License 1994 - 2015
Publications & Presentations
PubMed
- 875 citationsAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.Jeffrey A. Cohen, Alasdair Coles, Douglas L. Arnold, Christian Confavreux, Edward Fox
Lancet. 2012-11-24 - 855 citationsAlemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trialAlasdair Coles, Cary Twyman, Douglas L. Arnold, Jeffrey A. Cohen, Christian Confavreux
Lancet. 2012-11-24 - 28 citationsSuperior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MSDouglas L. Arnold, Elizabeth Fisher, Vesna V. Brinar, Jeffrey A. Cohen, Alasdair Coles
Neurology. 2016-10-04
Press Mentions
Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s DiseaseDecember 4th, 2019- Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424April 30th, 2019
Grant Support
- B Cell Responses To SHIVNational Institute Of Allergy And Infectious Diseases1999–2003
- Cloning Hiv-1-Neutralizing Fabs From LN Tissue SectionsNational Institute Of Allergy And Infectious Diseases1999–2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
